Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has informed that the US FDA conducted an inspection at the Company’s Baska facility from 8 September 2025 to 19 September 2025. The US FDA has subsequently determined that the inspection classification status of this facility is Official Action Indicated (OAI). The company continue to manufacture and supply approved products from the facility to the US market. The company will work with the regulator to achieve fully compliant status.

The above information is a part of company’s filings submitted to BSE.